|1.||Salazar-Onfray, Flavio: 4 articles (07/2014 - 02/2009)|
|2.||González, Fermín E: 4 articles (07/2014 - 02/2009)|
|3.||López, Mercedes N: 4 articles (07/2014 - 02/2009)|
|4.||Pereda, Cristián: 3 articles (07/2014 - 04/2011)|
|5.||Hermoso, Marcela: 2 articles (11/2012 - 04/2011)|
|6.||Tittarelli, Andrés: 2 articles (11/2012 - 04/2011)|
|7.||García, Tamara: 2 articles (11/2012 - 04/2011)|
|8.||Muñoz, Leonel: 2 articles (11/2012 - 02/2009)|
|9.||Saffie, Carlos: 2 articles (11/2012 - 04/2011)|
|10.||Mendoza-Naranjo, Ariadna: 2 articles (04/2011 - 02/2009)|
|1.||Melanoma (Melanoma, Malignant)
07/01/2014 - "Our results confirmed that TRIMEL induces a phenotypic maturation and increases the expression of surface CCR7 on melanoma patient-derived DCs, and also on the monocytic/macrophage cell line THP-1. "
04/15/2011 - "TRIMEL induced a committed, mature, DC-like phenotype in TAPCells and effectively activated melanoma-specific CD4(+) and CD8(+) T cells. "
04/15/2011 - "In particular, we identified factors present in a lysate derived from heat-shocked allogeneic melanoma cells (TRIMEL) that are associated with TAPCells' enhanced capability to induce CD8(+) T-cell responses in vitro and in vaccinated melanoma patients. "
02/20/2009 - "The aim of this work was to assess immunologic response, disease progression, and post-treatment survival of melanoma patients vaccinated with autologous dendritic cells (DCs) pulsed with a novel allogeneic cell lysate (TRIMEL) derived from three melanoma cell lines. "
09/17/2013 - "Recently, we produced a tumour antigen-presenting cells (TAPCells) vaccine using a melanoma cell lysate, called TRIMEL, as an antigen source and an activation factor. "
07/01/2014 - "We have previously reported a novel method for the production of tumour-antigen-presenting cells (referred to as TAPCells) that are currently being used in cancer therapy, using an allogeneic melanoma-derived cell lysate (referred to as TRIMEL) as an antigen provider and activation factor. "
11/01/2012 - "Recently, we reported a method for the production of therapeutic DCs against melanoma, called tumor antigen-presenting cells (TAPCells), using a heat-shocked allogeneic melanoma cell lysate (TRIMEL) as an activation factor and antigen provider. "
|5.||Prostatic Neoplasms (Prostate Cancer)
09/17/2013 - "Herein, we investigated the effect of TAPCells loaded with prostate cancer cell lysates (PCCL) as an antigen source, and TRIMEL as a dendritic cell (DC) activation factor; which were co-injected with the Concholepas concholepas haemocyanin (CCH) as an adjuvant on castration-resistant prostate cancer (CRPC) patients. "